European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesHumansFemalePregnancyNatalizumabMultiple Sclerosis
Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants.
Peilin Zhou, Chenming Zhong, Wanhong Wu, Meng Ke, Jianwen Xu, Rongfang Lin, Pinfang Huang, Cuihong Lin
Published: 202510.1016/j.ejps.2025.107301
Abstract
Natalizumab (NAT) is a monoclonal antibody that targets integrin α4 (anti-ITGA-4), approved by the FDA for treating multiple sclerosis (MS). However, the optimal timing of the final dose during pregnancy and the postponement of vaccinations for infan…
Preview only. Read the full abstract at the source